 |
Wuhan Nutra Biotechnology Co., Ltd.ISRIB ,Cosmetic Peptide, Tideglusib ,Way316606,Nootropics |
    
   
|
|||
Contact Us
E-mail: catherine@nutrabiotechchem.com
Prucalopride Succinate
Product Description:
Product Name: Prucalopride Succinate
Synonyms: Butanedioic acid 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide;Prucalopride Succinate;Prucalopride Succinate API;PRUCALOPRIDE INTERMEDIATES;Prucalopride Succinat;Prucalopride Succinate WS;Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide (1:1);Prucalopride Impurity
CAS: 179474-85-2
MF: C18H26ClN3O3.C4H6O4
MW: 485.95838
Prucalopride (brand name Resolor, developed by Johnson & Johnson and licensed to Movetis) is a drug acting as a selective, high affinity 5-HT4 receptor agonist[1] which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.Prucalopride was approved for use in Europe in 2009, in Canada (named Resotran) on December 7, 2011[9] and in Israel in 2014[10] but it has not been approved by the Food and Drug Administration for use in the United States. The drug has also been tested for the treatment of chronic intestinal pseudo-obstruction.
Synonyms: Butanedioic acid 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide;Prucalopride Succinate;Prucalopride Succinate API;PRUCALOPRIDE INTERMEDIATES;Prucalopride Succinat;Prucalopride Succinate WS;Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide (1:1);Prucalopride Impurity
CAS: 179474-85-2
MF: C18H26ClN3O3.C4H6O4
MW: 485.95838
Prucalopride (brand name Resolor, developed by Johnson & Johnson and licensed to Movetis) is a drug acting as a selective, high affinity 5-HT4 receptor agonist[1] which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.Prucalopride was approved for use in Europe in 2009, in Canada (named Resotran) on December 7, 2011[9] and in Israel in 2014[10] but it has not been approved by the Food and Drug Administration for use in the United States. The drug has also been tested for the treatment of chronic intestinal pseudo-obstruction.
Links:
Copyright © Wuhan Nutra Biotechnology Co., Ltd. All right reserved
